learn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
Search
forLearn
1 / 1 resultsResearch
5 / 1000+ results
research Global Impact of Coronavirus Disease 2019 (COVID-19)
COVID-19 has widely affected health, various industries, and the economy, but also led to more remote work and less pollution.
research The Imbalance Between Type 17 T-Cells And Regulatory Immune Cell Subsets In Psoriasis Vulgaris
Psoriasis involves an imbalance between certain immune cells, and targeting these could help restore skin health.
research Recent Approaches of Antibody Therapeutics in Androgenetic Alopecia
Antibody treatments show promise for hair loss but need more research.
research Monovalent Antibody-Conjugated Lipid-Polymer Nanohybrids for Active Targeting to Desmoglein 3 of Keratinocytes to Attenuate Psoriasiform Inflammation
The targeted nanohybrids effectively reduced psoriasis symptoms and improved skin health.
research Kinase Inhibition with BAY 43-9006 in Renal Cell Carcinoma
BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.
Community Join
5 / 27 resultscommunity UPDATE: The theory that explains everything. Please help me make this big!
Hair loss theory involves 3alpha-hydroxysteroid reductase (3AHD) converting DHT to androstenol. Discussion explores potential treatments and encourages more research.
community Residents of Victoria, Australia, sign up for a monoclonal antibody clinical trial – potential cure
A monoclonal antibody clinical trial for potential hair loss treatments in Victoria, Australia and the discussion of their efficacy. People shared information about similar drugs already on the market, speculated about potential side effects, and discussed how to spread the word about the trial.
community HMI-115 question about potential earliest access
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.
community Hope Medicine HMI-115 got 28M$ investment
Hope Medicine received a $28M investment for HMI-115, a monoclonal antibody in phase II trials for treating androgenetic alopecia. Some users are skeptical about its effectiveness, while others find the investment and trial results encouraging.
community Finally, some real breakthroughs. A comparison of the two leading baldness treatments: PP405 versus ABS-201
PP405 and ABS-201 are promising treatments for male pattern baldness. PP405 shows rapid hair growth in human trials, while ABS-201 shows significant regrowth in animal studies but is still in early human trials.